377,033 Shares in Outset Medical, Inc. $OM Bought by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. acquired a new stake in Outset Medical, Inc. (NASDAQ:OM) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 377,033 shares of the company’s stock, valued at approximately $5,324,000. Assenagon Asset Management S.A. owned about 2.12% of Outset Medical at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Legal & General Group Plc purchased a new position in Outset Medical in the 2nd quarter valued at about $34,000. Ameritas Investment Partners Inc. purchased a new position in shares of Outset Medical during the 2nd quarter worth $35,000. BNP Paribas Financial Markets increased its stake in Outset Medical by 7,013.8% in the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock valued at $40,000 after purchasing an additional 2,034 shares during the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new stake in Outset Medical in the 2nd quarter worth about $78,000. Finally, New York State Common Retirement Fund purchased a new position in shares of Outset Medical during the 2nd quarter worth about $108,000.

Wall Street Analyst Weigh In

Several equities analysts recently commented on OM shares. BTIG Research reaffirmed a “buy” rating and set a $17.00 price target on shares of Outset Medical in a research report on Tuesday, December 16th. Wall Street Zen raised Outset Medical from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th. Stifel Nicolaus set a $14.00 price objective on Outset Medical and gave the company a “buy” rating in a research note on Tuesday, November 11th. Weiss Ratings restated a “sell (e+)” rating on shares of Outset Medical in a report on Monday, December 15th. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $7.00 price target on shares of Outset Medical in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Outset Medical presently has an average rating of “Moderate Buy” and an average target price of $12.67.

Outset Medical Trading Up 2.5%

OM opened at $3.70 on Monday. Outset Medical, Inc. has a 12-month low of $3.59 and a 12-month high of $25.35. The company has a debt-to-equity ratio of 0.69, a current ratio of 7.09 and a quick ratio of 5.77. The stock has a market capitalization of $67.17 million, a PE ratio of -0.28 and a beta of 2.03. The firm’s fifty day moving average price is $8.26 and its 200 day moving average price is $13.50.

Outset Medical Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.